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Abstract Cardiac remodeling after myocardial injury
involves inflammation, angiogenesis, left ventricular hyper-
trophy and matrix remodeling. Thrombospondins (TSPs)
belong to the group of matricellular proteins, which are non-
structural extracellular matrix proteins that modulate cell–
matrix interactions and cell function in injured tissues or
tumors. They interact with different matrix and membrane-
bound proteins due to their diverse functional domains. That
the expression of TSPs strongly increases during cardiac
stress or injury indicates an important role for them during
cardiac remodeling. Recently, the protective properties of
TSP expression against heart failure have been acknowl-
edged. The current review will focus on the biological role of
TSPs in the ischemic and hypertensive heart, and will
describethefunctional consequences ofTSPpolymorphisms
in cardiac disease.
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Abbreviations
ACE Angiotensin converting enzyme
Ang-2 Angiopoietin-2
Ang-II Angiotensin-II
AT1R Angiotensin type I receptor
AVP Arginine-vasopressin
ECM Extracellular matrix
ERK Extracellular-regulated kinase
FAK Focal adhesion kinase
HF Heart failure
IAP Integrin-associated protein
ILK Integrin-linked kinase
LRP1 Low density lipoprotein-related
scavenger receptor
LVH Left ventricular hypertrophy
MI Myocardial infarction
MMP Matrix metalloproteinase
NO Nitric oxide
PAI Plasminogen activator inhibitor
PI3K Phosphatidyl inositol 3-kinase
RAS Renin-angiotensin system
SHR Spontaneously hypertensive rat
SNP Single nucleotide polymorphism
TGF-β1 Transforming growth factor β1
TIMP Tissue inhibitor of metalloproteinases
TSP Thrombospondin
tTG Tissue transglutaminase
VEGF Vascular endothelial growth factor
VSMC Vascular smooth muscle cell
WKY Wistar-Kyoto
WT Wild-type
Introduction
Heart failure (HF) is a condition resulting from different
cardiovascular diseases and is one of the leading causes
of mortality in Western society (Braunwald 1997; Vasan
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(MI), hypertensive heart disease, myocarditis, and genetic
cardiomyopathies are diseases that involve extensive
cardiac remodeling, and often result in an increased risk
of developing HF. Cardiac dysfunction after injury or
stress is the outcome of a complex interplay between
environmental and mechanical forces, different cell types,
and various molecular processes that determine cell
behavior. In vivo and in vitro studies have identified
different mechanisms like the renin-angiotensin system
(RAS) (Rosenkranz 2004), integrin-signaling (Lal et al.
2009; Manso et al. 2006), and matrix remodeling (Spinale
2007), among many others implicated in the progression
of HF.
The extracellular matrix (ECM) is a crucial system for
maintaining strength and organization of the cardiac tissue,
and cardiac cell communication. The ECM forms a
complex meshwork composed of structural proteins (such
as type I and III collagen), proteoglycans, glycosaminogly-
cans, and a basement membrane, which together are
responsible for tissue strength and structure. Matricellular
proteins are non-structural proteins with a minimal expres-
sion in the normal heart. However, their expression
increases after injury, where they modulate cell function
and behavior through regulation of cell–cell and cell–matrix
interactions (Spinale 2007).
Alterations in ventricular shape, size and function take
place during cardiac injury, a process termed remodeling
[reviewed in (Spinale 2007; Swynghedauw 1999)].
Matricellular proteins appear to be key players during
cardiac remodeling (Schellings et al. 2004). Animal
experiments revealed that the matricellular proteins
thrombospondin 1 (TSP-1) (Frangogiannis et al. 2005),
thrombospondin 2 (TSP-2) (Schroen et al. 2004), osteo-
pontin (Collins et al. 2004; Trueblood et al. 2001),
periostin (Shimazaki et al. 2008), and SPARC (Schellings
et al. 2009) all protect the heart from developing pump
failure. Among the matricellular proteins, thrombospon-
dins (TSPs) were highlighted as important players in the
process of cardiac remodeling (Chatila et al. 2007). This
review summarizes our current knowledge of the role of
TSPs, in particular TSP-1 and TSP-2, in cardiac remodel-
ing during hypertrophy and after MI (Table 1). It will
elaborate the molecular characteristics of TSPs that may
relate to their role in preventing HF (Figs. 1 and 2).
Thrombospondins in cardiac homeostasis
Although the expression of thrombospondins is low in the
normal, unstressed heart, recent evidence suggests that they
are important in modulating physiological angiogenesis and
blood pressure (Isenberg et al. 2009b; Krady et al. 2008).
Global deletion of TSP-1 resulted in significant increases in
cardiac and skeletal muscle capillarity, which was associ-
ated with increased basal levels of vascular endothelial
growth factor (VEGF) in TSP-1-null mice (Malek and
Olfert Ph 2009). Together with the effects of TSP-1 on
endothelial cell activity, this finding indicates that TSP-1 is
important in regulating physiological angiogenesis. The
influence of TSP-2 on physiological angiogenesis was
demonstrated in a three-dimensional angiogenesis assay in
which TSP-2 limited angiogenesis by decreasing gelatino-
lytic activity, and by accelerated recovery of blood flow in
TSP-2-null mice after hind limb ischemia. Also, increased
endothelial cell organization and migration was observed
when these cells were cultured on TSP-2-null ECM. Thus,
TSP-2 can inhibit physiological angiogenesis by limiting
the gelatinolytic activity of endothelial cells and by its
influence on ECM structure. In addition to the effects of
TSPs on physiological angiogenesis, recent evidence
suggests that TSP-1 is able to modulate nitric oxide
(NO) controlled blood pressure via its receptor CD47/
integrin associated protein (CD47/IAP) (Isenberg et al.
2009b).
Thrombospondins in hypertrophic cardiac remodeling
Cardiac hypertrophy, an increase in heart muscle mass,
reflects an adaptation of the myocardium in response to
increased mechanical stress or volume overload. It occurs
as a physiological response, often seen in athletes, or as a
pathologic one, which is associated with maladaptive
changes. Persistent pathological hypertrophy finally
evolves in cardiac dysfunction and clinical HF. Apart from
mechanical stress, various growth factors and other stimuli
can induce cellular signaling events that lead to hypertro-
phy. Although cardiac myocytes play an important role in
the hypertrophic process, other cell types such as fibro-
blasts, endothelial cells, and smooth muscle cells may also
affect the hypertrophic response (Gupta et al. 2007).
The ECM plays an important role in hypertrophic
remodeling by providing architectural support to the cardiac
tissue, and mediating cell-ECM communication. Here, the
different mechanisms by which TSPs may affect hypertro-
phic cardiac remodeling will be discussed.
Thrombospondin expression in cardiac hypertrophy
Expression of TSP-1, TSP-2, and TSP-3 was increased
during heart failure in a model of hypertensive hypertrophic
remodeling (Schroen et al. 2004) (Table 1). The homozy-
gous renin transgenic TGR(mRen2)27 rat suffers from
severe hypertension that leads to cardiac hypertrophy at
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decompensation at 12–14 weeks of age. Biopsies taken at
10 weeks of age allowed retrospective comparison of gene
expression between the decompensated and compensated
group. TSP-1, TSP-2, and TSP-3 transcript levels were all
significantly enhanced at 10 weeks of age in the rats prone
to develop quick decompensation. Moreover, TSP-2 tran-
script levels were also increased in patients with cardiac
hypertrophy, secondary to aortic stenosis, and TSP-2
expression was particularly elevated in patients with a
depressed ejection fraction (<55%) (Schroen et al. 2004).
Other in vivo studies demonstrated enhanced expression of
TSP-1 after transverse aortic constriction and sustained
alpha-adrenergic drive (Chaulet et al. 2006; D. Wang et al.
2003) (Table 1). A study by Rysä et al. identified the
pentameric, B-type TSP-4 to be increased in the hearts of
spontaneously hypertensive rats (SHR) in comparison to
age-matched Wistar Kyoto rats (WKY) (Rysa et al. 2005)
(Table 1). The expression of TSP-4 transcripts gradually
increased with age in the SHR, with the highest levels at
20 months of age. TSP-4 expression is also enhanced in
response to acute pressure overload induced by
angiotensin-II (Ang-II) and arginine-vasopressin (AVP)
infusion (Mustonen et al. 2008) (Table 1). Ang-II infusion
resulted in a rapid increase in left ventricular (LV) TSP-4
mRNA levels, the highest at 6 h after infusion. AVP
Fig. 2 Potential functions of TSP-2 in cardiac remodeling. Together
with TSP-1, TSP-2 is an inhibitor of angiogenesis, and through
integrin-binding TSP-2 might also influence adhesive or stretch-
induced signaling. An important feature of TSP-2 is its capacity to
bind pro- or active MMP-2, resulting in endocytosis via the LRP-
receptor, and inhibition of its proteolytic activity. The influence of
TSP-2 on collagen maturation has also been established. α indicates
α-integrin subunit, β indicates β-integrin subunit, fak focal adhesion
kinase; ilk integrin-linked kinase; MMP matrix metalloproteinase; LRP
low density lipoprotein receptor
Fig. 1 Potential functions of TSP-1 in cardiac remodeling during
pressure overload or after MI. TSP-1 is an inhibitor of angiogenesis
and an activator of TGF-β1, and thereby influences the behavior of
endothelial cells, fibroblasts and myocytes. By binding to integrins,
TSP-1 might also alter the adhesive or stretch-induced signaling of
cells. α indicates α-integrin subunit, β indicates β-integrin subunit,
fak focal adhesion kinase; ilk integrin-linked kinase; Alk activin-like
kinase; LVH left ventricular hypertrophy; TGF β transforming growth
factor beta
Table 1 Expression of TSPs and cardiac phenotypes of different TSP null mice in cardiac pathologies
Expression TSP null cardiac phenotype References
Pressure
overload
MI Pressure
overload
MI
TSP-1 Increased Increased
during early
phase
ND Increased inflammatory response;
More extensive postinfarct
remodeling
[Chaulet et al. 2006; Frangogiannis et al.
2005; Schroen et al. 2004; Wang et al.
2003]
TSP-2 Increased ND Severe cardiac
failure and cardiac
rupture
>90% Cardiac rupture within
3 days
[Cleutjens et al. 1999; Schroen et al.
2004]
TSP-3 Increased ND ND ND [Schroen et al. 2004]
TSP-4 Increased ND ND ND [Mustonen et al. 2008; Rÿsa et al. 2005;
Tan et al. 2002]
Thrombospondins and cardiac remodeling 203infusion also increased TSP-4 expression, that was limited
to LVendothelial cells (Mustonen et al. 2008). Furthermore,
TSP-4 was upregulated at an early stage in response to
cardiac overload, similar to TSP-1 (Mustonen et al. 2008).
TSP-4 expression also increased significantly in patients
with end-stage dilated cardiomyopathy (Tan et al. 2002)
(Table 1). These studies indicate an important role for TSP-
1, -2, -3, and -4 in left ventricular hypertrophic cardiac
remodeling following pressure overload.
ECM remodeling during cardiac hypertrophy:
thrombospondins and the MMP-TIMP balance
Matrix metalloproteinases (MMPs) and tissue inhibitor of
metalloproteinases (TIMPs) are actively involved in the
process of hypertrophic cardiac remodeling (Spinale 2007).
MMPs degrade ECM proteins and are divided into four
classes:(1) collagenases, which include MMP-1, -8, -13,
and -18; (2) the gelatinases, which include MMP-2, and -9;
(3) the stromelysins, including MMP-3, -10, and -11; and
(4) the membrane-type MMPs (MT-MMPs), including
MMP-14, -17, -24, and -25. The TIMP family consists of
4 family members: TIMP1-4. In the uninjured heart, a
balance between the synthesis and breakdown of ECM is
maintainedby MMPs andTIMPs (Spinale 2007). During the
transition of cardiac hypertrophy to heart failure, however,
the balance shifts towards increased MMP activity, leading
to myocyte slippage and ventricular dilatation.
TSP-1 and TSP-2 share a large overall similarity in
their protein structure and therefore interact with the same
ligands. Both TSP-1 and TSP-2 contain three different
repeated sequence motifs (TSRs), known as type 1, type
2, and type 3 repeats. These TSRs allow TSP-1 and TSP-
2 to interact with MMPs, thereby regulating the activity of
these proteinases (Emonard et al. 2004; Yang et al. 2000).
TSP-2-null skin fibroblasts have a defect in attachment to
different matricellular proteins in vitro as a consequence of
increased levels of active MMP-2 (Yang et al. 2000). In
addition, the increased activity of MMP-2 causes enhanced
proteolysis of cell-surface tissue transglutaminase (tTG), an
enzyme important for collagen cross-linking (Agah et al.
2005). Later, it was demonstrated that TSP-2 is actively
involved in the clearance of MMP-2 by directly targeting
MMP-2 to form a complex that is endocytosed by the low
density lipoprotein-related scavenger receptor (LRP1)
(Yang et al. 2001) (Fig. 2). In a model of dermal wound
healing, mice that lack TSP-2 showed aberrant ECM
remodeling associated with increased levels of MMP-2,
MMP-9, TIMP-1 and TIMP-2 (Maclauchlan et al. 2009). In
concordance, TSP-2-null mice had increased MMP-2
activity after infusion of angiotensin II, contributing to an
increased incidence of left ventricular rupture and dilatation
(Schroen et al. 2004).
Whether TSP-1 may also regulate MMP activity is less
certain, depending on cell-type specific actions of TSP-1. It
increases MMP-9 activity in endothelial cells and in gastric
cancer (Albo et al. 2002; Qian et al. 1997), whereas others
reported an inhibition of tumor growth by TSP-1 via its
attenuation of MMP-9 activity (Rodriguez-Manzaneque et
al. 2001). In vascular smooth muscle cells, TSP-1 induced
MMP-2 activity (Lee et al. 2003), but the mechanism
remains unclear. The contradictory results of TSP-1 on the
regulation of MMP activation may depend on the opposite
effects exerted by the different domains of TSP-1. Tarabo-
letti et al. reported that, in rabbit corneal endothelial cells,
the 25-kDa heparin-binding domain of TSP-1 increased
MMP-2 and MMP-9 activity and decreased TIMP-2 levels,
whereas the 140 kDa carboxy-terminal fragment of TSP-1
upregulated TIMP-2 expression and inhibited MMP-2 and
MMP-9 activities (Taraboletti et al. 2000). Similar experi-
ments with capillary endothelial cells isolated from bovine
hearts confirmed these results (Donnini et al. 2004).
Reports on the influence of TSP-3, TSP-4, and TSP-5 on
MMP activity are lacking.
Thrombospondins and the renin-angiotensin system (RAS)
in cardiac hypertrophy
The RAS is activated in response to pressure overload of
the heart, and contributes to the process of myocardial
remodeling (Heineke and Molkentin 2006; Rosenkranz
2004). The effector molecule of the RAS, angiotensin-II
(Ang-II), triggers cell-specific responses in cardiac fibro-
blasts and myocytes through binding to the angiotensin
type I receptor (AT1R) (Crabos et al. 1994; Miyata and
Haneda 1994; Schorb et al. 1993; Villarreal et al. 1993).
Binding of Ang-II to the AT1R induces synthesis of the
locally secreted growth factor transforming growth factor
β1 (TGF-β1) in cardiac fibroblasts and myocytes. Interac-
tion of TGF-β1 with its receptor causes expression of ECM
proteins, collagen synthesis, and proliferation of cardiac
f i b r o b l a s t s( E g h b a l ie ta l .1991;H e i m e re ta l .1995;
Sappino et al. 1990; Tomasek et al. 2002; Villarreal et al.
1996). Tissue culture experiments showed that the paracrine
release of TGF-β1 from fibroblasts mediates Ang-II
induced hypertrophy of cardiac myocytes as blocking
antibodies to TGF-β1 abolished myocyte growth (Gray et
al. 1998). Also, blockade of the AT1R inhibits the
expression of TGF-β1 as well as the resulting cardiac
hypertrophy and fibrosis, indicating a crucial link between
Ang-II and TGF-β1 (Tokuda et al. 2004; Tomita et al.
1998). Further support for the link between the RAS and
TGF-β1 is provided by studies that show upregulation of
TGF-β1 in patients with idiopathic hypertrophic cardiomy-
opathy and dilated cardiomyopathy (Casscells et al. 1990;
Hao et al. 1999; Takahashi et al. 1994; Thompson et al.
204 M.W.M. Schellings et al.1988; Tomita et al. 1998; Villarreal and Dillmann 1992;
Wunsch et al. 1991), and upregulation of angiotensin
converting enzyme (ACE) and TGF-β1 in pressure-
overloaded human hearts is correlated with the degree of
fibrosis (Hein et al. 2003).
From the sequence similarity between TSP-1 and TSP-2,
it could be expected that the binding partners of TSP-1 also
interact with TSP-2. The type I repeats, which are
characteristic for both TSP-1 and TSP-2, have been
described in the activation of latent TGF-β1 by TSP-1
(Schultz-Cherry et al. 1995). The activation of TGF-β1
links TSP-1 to the process of hypertrophic cardiac
remodeling (Fig. 1). As indicated above, TSP-1 is increased
in cardiac hypertrophy. Activation of latent TGF-β1
involves direct interaction with two sequences in the type
1 repeats of TSP-1. The KRFK sequence in the first TSR
activates latent TGF-β1, whereas the GGWSHW sequence
binds active TGF-β1 and potentially orients the TSP
molecule (Schultz-Cherry et al. 1995). TSP-2 lacks the
KRFK sequence in the TSR, but contains the GGWSHW
motif, and therefore can bind, but not activate TGF-β1. The
significance of TSP-1-mediated TGF-β1 activation is
supported by studies in vivo. Histological abnormalities,
e.g., leukocyte infiltration and inflammatory changes in the
lung and pancreas, are strikingly similar in young TSP-1-
null mice and TGF-β1-null mice (Crawford et al. 1998).
Moreover, these abnormalities could be partially reversed
by treatment of TSP-1-null mice with KRFK, a TSP-1-
derived peptide that binds the KRFK motif and activates
TGF-β1. The synthetic peptide GGWSHW, based on a
sequence in the TSR of TSP-1 and TSP-2, inhibited
activation of TGF-β1 by TSP-1. In addition, TSP-2 inhibits
activation of latent TGF-β1 by TSP-1, presumably via
competitive binding to TGF-β1 when both TSPs are present
(Schultz-Cherry et al. 1995). Whether this possibility is the
case in remodeling tissues is questionable, since the
expression of TSP-1 and TSP-2 is differentially controlled
(Bornstein et al. 2004). Recently, the importance of TSP-1-
mediated TGF-β1 activation during cardiac remodeling has
been shown, as a peptide antagonist of TSP-1-dependent
TGF-β1 activation prevented fibrosis and improved cardiac
function (Belmadani et al. 2007). Analyses of active
TGF-β1 levels in TSP-2-null mice during LVH would
provide an insight in the role of TSP-1 and TSP-2
expression in controlling TGF-β1 activation during LVH
remodeling.
Thrombospondin–integrin interaction in cardiac
hypertrophy
Integrins and CD47/IAP are cell surface receptors that
are important in physiological cell functioning by
mediating interactions between cells and their ECM. In
addition to their structural role in the anchoring of cells,
integrins participate in signal transduction from the
“outside to inside” and “inside to outside” of the cell
(Lal et al. 2009). Therefore, integrin and CD47/IAP
signaling plays a crucial role in controlling cell behavior
in response to various stimuli, via regulation of processes
such as cell adhesion, migration, proliferation, survival
and apoptosis (Isenberg et al. 2008b; Lal et al. 2009). In
the heart, integrins are involved in normal cardiac
mechanotransduction, and have been shown to be indis-
pensible during cardiac remodeling (Shai et al. 2002).
Focal adhesion kinase (FAK) and integrin-linked kinase
(ILK) are downstream targets of integrin signaling and are
implicated in cardiac remodeling (Lal et al. 2009). FAK-
null mice developed dilated cardiomyopathy in response
to pressure overload due to the lack of a proper hyper-
trophic response (DiMichele et al. 2006). Zebrafish with
a mutation in the ILK-gene and ILK-null mice both
display spontaneous cardiac failure (Bendig et al. 2006;
White et al. 2006), and ILK expression has been
associated with the development of cardiac hypertrophy
(Lu et al. 2006).
Together these studies emphasize that interactions
with integrins and subsequent activation of its down-
stream targets are involved in cardiac failure. Several
studies have identified TSPs as ligands for integrins and
CD47/IAP. The RGD-containing type-3 repeat of TSP-1
was reported to interact with αvβ3i n t e g r i ni nh u m a n
endothelial cells to mediate cell adhesion in vitro
(Staniszewska et al. 2007). Four β1 integrin binding
sites have been mapped to the N-terminus of TSP-1. The
α3β1 integrin recognizes a NVR motif and stimulated
angiogenesis and endothelial cell behavior (Chandrasekaran
et al. 2000;K r u t z s c he ta l .1999). A second integrin, α4β1,
was mapped to the LDVP sequence in TSP-1 that was also
conserved in TSP-2. Interaction of TSP-1 with α4β1o n
vascular endothelial cells regulates angiogenesis in vivo
and affects cell proliferation, adhesion, and migration in
vitro (Calzada et al. 2004). Like α4β1, the binding site for
α6β1 was conserved in both TSP-1 and TSP-2 and was
reported to mediate adhesion and chemotaxis of microvas-
cular endothelial cells (Calzada et al. 2003). Recently, a
fourth integrin, α9β1, was recognized as a receptor for
TSP-1 that induces endothelial cell proliferation and
migration and thereby modulates angiogenesis (Staniszewska
et al. 2007). In vascular smooth muscle cells (VSMC),
TSP-1 can induce FAK phosphorylation, which is essential
for migration (Gahtan et al. 1999;X .J .W a n ge ta l .2008).
In addition, Gao et al. showed that TSP-1 also binds to
CD47/IAP that in turn associates with αvβ3 and leads to cell
spreading, an activity that was correlated with increased
FAK phosphorylation (Gao et al. 1996). These studies
clearly demonstrate a role for TSPs in the modulation of
Thrombospondins and cardiac remodeling 205integrin signaling, particularly in endothelial cells and
VSMC during vascular remodeling. Although TSPs are
recognized as binding partners of integrins and CD47/IAP
and can activate FAK, no direct evidence for a role of TSPs
in the stretch-sensing machinery is available. Therefore,
their importance in the integrin-mediated hypertrophic
response remains to be elucidated.
Thrombospondins and angiogenesis in cardiac hypertrophy
TSP-1 and TSP-2 are recognized as potent inhibitors of
angiogenesis [reviewed in (Armstrong and Bornstein 2003)
and see review by Bornstein in this issue]. TSPs exert their
anti-angiogenic effects through several mechanisms: inhi-
bition of endothelial cell-cycle progression, prevention of
endothelial cell mobilization, and/or induction of endothe-
lial cell apoptosis (Armstrong et al. 2002; Rodriguez-
Manzaneque et al. 2001; Simantov and Silverstein 2003)
(Figs. 1 and 2). In addition, TSP-2 influences angiogenesis
through modulation of MMP activity (Krady et al. 2008).
Pathological hypertrophy is associated with a reduced
capillary density, as found in several human cardiac
diseases (Hudlicka et al. 1992; Karch et al. 2005). NO
and Akt signaling are important in the process of
angiogenesis and have been implicated in physiological
and pathological cardiac function (Rastaldo et al. 2007).
First recognized as an endothelial-derived relaxing factor
(Ignarro et al. 1987), NO is produced through conversion of
L-arginine to L-citrulline by three NO synthases (nNOS,
eNOS, and iNOS) (Isenberg et al. 2008a). In the heart, NO
limits cardiac remodeling after MI and participates in the
control of heart rate and contractility (Rastaldo et al. 2007).
In comparison with WT explants, TSP-1-null tissue
explants show an enhanced angiogenic response elicited
by NO (Isenberg et al. 2005). NO induced endothelial cell
proliferation, associated with a decrease in TSP-1 levels
that was dependent on phosphorylation of ERK, whereas
exogenous TSP-1 can suppress NO mediated ERK phos-
phorylation, data indicating a feedback loop between TSP-1
and NO (Ridnour et al. 2005). NO stimulates endothelial
cell motility and adhesion to type I collagen in a cGMP-
dependent manner. Picomolar concentrations of exogenous
TSP-1 potently block NO-mediated stimulation of cGMP
(Isenberg et al. 2005). In addition, recombinant type-1
repeats of TSP-1 and a CD36 agonist antibody have a
similar effect, whereas the N-terminal domain of TSP-1 did
not inhibit NO-mediated stimulation of cGMP. These
results indicate that the inhibitory effects of TSP-1 on
pro-angiogenic NO signaling are mediated through binding
to CD36. Later, it was reported that TSP-1 inhibits NO
stimulated responses in vascular smooth muscle cells in an
identical manner as previously described in endothelial
cells (Isenberg et al. 2006b). A study in CD47/IAP-null
cells demonstrated that, whereas ligation of CD36 is
sufficient to block NO-mediated responses in VSMC and
endothelial cells, only CD47/IAP is crucial for TSP-1 to
exert its inhibitory effects (Isenberg et al. 2006a). TSP-2
shares the C-terminal binding motif for CD47/IAP with
T S P - 1 ,a n db o t hT S P sh a v eb e e nf o u n dt or e g u l a t e
inflammatory responses through this receptor (Lamy et al.
2007). However, TSP-2 binds less avidly to CD47/IAP-
expressing cells compared to TSP-1. Consistent with these
findings TSP-2 inhibits NO-mediated cGMP synthesis in
vascular cells less efficiently (Isenberg et al. 2009a).
Short-term and long-term Akt activation have different
effects on cardiac hypertrophy and angiogenesis (Shiojima
et al. 2005). Short-term activation of Akt in transgenic mice
results in physiological hypertrophy and concomitant
enhanced angiogenesis, responses resulting in maintenance
of vascular density (Shiojima et al. 2005). This capillary
growth is mediated by increased expression of VEGF and
angiopoietin-2 (Ang-2) after short-term Akt activation,
which is dependent on mTOR (Shiojima et al. 2005).
Long-term activation of Akt, on the other hand, results in
down regulation of VEGF and Ang-2, possibly due to
decreased expression of mTOR, and is accompanied by a
decrease in capillary density. Akt-null mice displayed
enhanced angiogenic responses and an ECM reduced in
density, which may facilitate growth of new capillaries in
the skin of Akt-null mice (Chen et al. 2005). Importantly,
the observed abnormalities in collagen organization, en-
hanced angiogenesis, and vascular leakage, closely resem-
ble the phenotype of mice lacking TSP-1 and TSP-2 (Chen
et al. 2005). TSP-1 and TSP-2 are decreased in the tissues
of Akt-null mice, and the increased angiogenesis found in
these animals could be normalized by re-expression of
TSP-1 and TSP-2 (Chen et al. 2005). Thus, the overall
effect of Akt on angiogenesis is suppressive and involves
controlling the expression of angiostatic TSP-1 and TSP-2.
Recently, the link between TSPs and Akt in angiogenesis
was confirmed by a study demonstrating that TSP-1
modulates microvascular remodeling in the retina by
antagonizing Akt-signaling triggered by VEGF, whereas
no significant effects of TSP-2 were reported (Simantov et
al. 2005; Sun et al. 2009). Whether or not inhibition of
VEGF-induced Akt-signaling by TSP-1 depends on direct
blockade of VEGF signaling, or sequestration of Akt-
signaling, remains uncertain. Interestingly, recent evidence
revealed increased basal VEGF levels in TSP-1-null mice,
associated with increased capillary density in cardiac and
skeletal muscle. These data indicate that TSP-1 regulates
angiogenesis via a direct effect on VEGF (Malek and Olfert
Ph 2009). Whether the upregulation of TSPs during cardiac
hypertrophy is important for the balance between myocyte
and capillary growth, via modulation of NO- and/or Akt-
signaling, remains to be investigated.
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myocardial infarction
MI is one of the major risk factors in the development of
heart failure, and accounts for 62% of all cases (Bansal et
al. 2006). During MI, part of the heart is subjected to an
abrupt lack of perfusion that leads to rapid death of the
cardiac myocytes and the formation of a scar. Grossly,
infarct healing consists of three overlapping phases; the
inflammatory phase, the proliferative phase, and the
maturation phase (Frangogiannis 2006). The inflammatory
phase takes place within hours after the onset of MI and is
marked by the influx of leukocytes that remove the dead
myocytes, followed by the influx of other inflammatory
cells. Two to 3 days after MI, the onset of the proliferative
phase of infarct healing begins with the formation of
granulation tissue, which is rich in inflammatory cells and
myofibroblasts that are capable of producing large amounts
of ECM proteins. In parallel with the proliferation phase of
infarct healing, new blood vessels start to appear in the
infarcted area. Finally, after 2–3 weeks, the cell-rich
granulation tissue evolves into a mature, collagen-based
scar, characterized by the disappearance of cells and by the
cross-linking of secreted collagen. During all phases of
infarct healing, the composition of the ECM plays a crucial
role in regulating cell behavior by modulation of cell
phenotype and gene expression (Dobaczewski et al. 2006).
The following paragraphs discuss the expression and
function of TSPs during the three phases of wound healing
after MI. We discuss only TSP-1 and TSP-2 because they
are known to play a role in infarct healing.
Expression of TSPs after acute myocardial infarction
The expression of TSP-1 precedes that of TSP-2 and
partially overlaps it during the process of wound healing.
This important feature could explain some of the pheno-
types found in the respective null mice, as described below
(Table 1). TSP-1 is secreted by inflammatory cells, and its
expression is high during early phases of wound healing,
whereas TSP-2 is secreted mostly by fibroblasts, and is
therefore expressed at high levels during later stages of
wound healing (Agah et al. 2002; Bornstein et al. 2004).
Thrombospondins and the inflammatory response
A role of TSP-1 and TSP-2 in wound repair is suggested by
their dynamic expression pattern during the different phases
of wound healing. TSP-1 is secreted by inflammatory cells
during the acute phase of tissue repair, whereas its
expression drops during the proliferative phase of healing
(Agah et al. 2002). The role of TSP-1 in the inflammatory
phase after MI has been described by Frangogiannis et al.,
who discovered that TSP-1 prevents expansion of healing
myocardial infarcts (Frangogiannis et al. 2005) (Table 1).
First, TSP-1 expression was enhanced in a canine ischemia-
reperfusion model. Thereafter, they extended this model to
TSP-1-null and WT mice. In infarcted WT mice TSP-1
protein was noted after 24 h to 7 days, and expression was
localized to the border zone of the infarct (Frangogiannis et
al. 2005). TSP-1-null mice displayed higher levels of
chemokine and cytokine transcripts in healing infarcts,
which were associated with increased and prolonged
abundance of macrophages and myofibroblasts in the
infarct zone, as well as in remote, non-infarcted myocardi-
um. This observation indicates that TSP-1-null mice have
an increased inflammatory response after ischemia-
reperfusion, which correlates with the enhanced ventricular
dilation after MI in these animals. The mechanism
responsible for mediating the inflammatory response by
TSP-1 after MI is likely to involve the activation of local
TGF-β1. As previously discussed, TSP-1 is a major
activator of TGF-β1 in vivo (Crawford et al. 1998). In
non-infarcted murine hearts TSP-1 is not expressed, and
levels of chemokine and cytokine transcripts are similar
between WT and TSP-1-null animals. However, infarcted
hearts show a strong inflammatory response with marked
upregulation of TGF-β1 (Dewald et al. 2004). In addition,
infarcted hearts of TSP-1- null mice showed a trend
towards decreased phosphorylation of the intracellular
effector of TGF-β1, Smad2. Alternatively, the angiostatic
effects of TSP-1 may regulate infarct healing. However, no
differences in microvascular profiles between WT and TSP-
1- null mice were reported after MI (Frangogiannis et al.
2005). Therefore, the selective expression of TSP-1 in the
infarct border zone is suggested to function as a barrier that
locally suppresses inflammatory chemokines and cytokines
through its TGF-β1-activating effects, and prevents exten-
sion of the inflammatory process into the non-infarcted
area.
In contrast to TSP-1, the structurally similar TSP-2 does
not activate latent TGF-β1 and is therefore likely to affect
the inflammatory process through other mechanisms.
Different studies concerning the role of TSP-2 in the
inflammatory response reported contradictory results. In
oxazolone-induced inflammation of the skin, lack of TSP-2
results in an enhanced inflammatory response. TSP-2-null
mice exhibited increased angiogenesis, edema, and inflam-
matory infiltration (Lange-Asschenfeldt et al. 2002). More-
over, microvascular leakage was enhanced in the inflamed
skin of TSP-2-null mice, a result indicating that TSP-2
controls vascular permeability during inflammation. An-
other study showed similar phenotypes in CD47/IAP-,
TSP-1-, and TSP-2-null mice after oxazolone-induced
inflammation. The authors suggested that the observed
prolonged inflammation resulted from a deficiency in T-cell
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TSP-CD47/IAP interactions (Lamy et al. 2007). In contrast
to oxazolone-induced inflammation, the early phase of
dermal skin wound healing (0–4 days) did not differ
between WT and TSP-2-null mice, and there were no signs
of increased inflammatory infiltration. However, 7 days
after wounding, progressive and significant differences
were revealed between WT and TSP-2-null mice, the latter
showing accelerated healing with irregular granulation
tissue, and increased angiogenesis (Bornstein et al. 2004;
Kyriakides et al. 1999). Therefore, one might speculate that
TSP-2 affects the inflammatory response at a later phase of
wound healing, in comparison with TSP-1, presumably via
regulation of vascular permeability and T-cell apoptosis
during inflammation. With respect to the role of TSP-2 in
MI, a high incidence of cardiac rupture in TSP-2-null mice
within 3 days after acute MI was reported (Cleutjens et al.
1999). The inflammatory response in the hearts of these
TSP-2-null mice has not been evaluated. These findings
imply an important role for TSP-2 in controlling the
structural integrity during ECM remodeling in the heart.
Thrombospondins and the proliferative phase of infarct
healing
After the phase of acute inflammation, 2 to 3 days after MI,
granulation tissue begins to form in the border zone of the
infarct. Key features of this granulation tissue are the
abundance of inflammatory cells, myofibroblasts and small
blood vessels. Both TSP-1 and TSP-2 are potent inhibitors
of angiogenesis and exert their angiostatic effects via
interaction with CD36 and/or CD47/IAP (Isenberg et al.
2005; Simantov and Silverstein 2003) (Figs. 1 and 2). TSP-
1 mRNA is markedly induced 6–24 h after reperfusion, and
TSP-1 immunoreactivity showed specific localization in the
infarct border zone 7 to 28 days after MI. In addition, the
vascular network in TSP-1-null infarcts was comparable to
neovascularization in WT mice (Frangogiannis et al. 2005).
Consistent with these findings, angiogenesis has not been
found to be increased in skin wounds of mice lacking TSP-
1 (Agah et al. 2002). A plausible explanation for this
observation is that TSP-1 is not expressed during the late
proliferative phase and during remodeling, when neovascu-
larization occurs. TSP-1 is a major activator of latent TGF-
β1, an important factor in myofibroblast differentiation.
Surprisingly, TSP-1-null infarcts contained higher numbers
of myofibroblasts (Frangogiannis et al. 2005). These data
indicate that TSP-1 is more involved in controlling the
inflammatory response and preventing expansion of the
granulation tissue into the non-infarcted area, rather than
affecting angiogenesis, during this phase of wound healing.
The effects of TSP-2 on angiogenesis during the
proliferative phase after MI cannot be studied directly, due
to the early cardiac ruptures that occur in TSP-2-null
animals after acute MI (Cleutjens et al. 1999). However,
during cutaneous wound healing TSP-2 exhibits a time/
phase dependent expression pattern. In early wounds, when
there is increased angiogenesis, TSP-2 is sparse and can be
localized to a small number of fibroblasts. Levels of TSP-2
become high, and its expression widespread, during late
stages of healing, which coincide with ECM remodeling
and vascular regression (Kyriakides et al. 1999). In contrast
to TSP-1-null mice, TSP-2-null mice exhibited increased
vascular density after dermal wound healing together with
the presence of an abnormal, loosely organized collagen
matrix (Bornstein et al. 2004; Kyriakides et al. 1999).
These findings are consistent with the phenotypes of TSP-1
and TSP-2-null mice that show alterations in the early and
late phases of wound healing, respectively. TSP-2 is likely
to be important for controlling angiogenesis and the
integrity of the newly formed matrix during later phases
of infarct healing (Fig. 2).
Thrombospondins and maturation of the infarct scar
Maturation of the infarct scar is characterized by removal of
inflammatory cells, regression of blood vessels, and cross-
linking of the deposited collagen (Blankesteijn et al. 2001).
Since the levels of TSP-1 are low during late stages of
wound healing, the protein was expected to play a minor
role during infarct maturation. After ischemia-reperfusion,
TSP-1 was observed up to 28 days after injury; however, its
expression was highly selective for the infarct border zone,
and was minimal in the infarct center. These data support
the hypothesis that TSP-1 is not critical for infarct scar
maturation (Frangogiannis et al. 2005). However, TSP-1
could affect maturation of the infarct scar through the
activities of TGF-β1, as TGF-β1 is known to promote
fibrosis via enhanced collagen deposition (Lijnen et al.
2000)( F i g .1). Furthermore, TGF-β1 inhibits MMP
activities and increases synthesis of proteinase inhibitors
such as plasminogen activator inhibitor (PAI) and TIMPs
(Schiller et al. 2004). Consistent with these functions,
enhanced MMP-9 activity was reported in the infarct border
zone in the absence of TSP-1, which in turn could explain
the enhanced ventricular dilation after MI in TSP-1-null
mice. Whether TSP-1 is of significant importance during
this phase of late infarct healing remains to be determined.
In contrast to TSP-1, TSP-2 is expressed during the
phase of scar maturation, and TSP-2-null mice show
abnormalities in collagen fibril formation. TSP-2 might
therefore be an important regulator of infarct scar formation
(Kyriakides et al. 1998). By scanning electron microscopy,
abnormal loop-like fibers of large diameter were detected in
the dermis of TSP-2-null mice. In addition, transmission
electron microscopy showed that collagen fibrils in the
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comparison to WT fibrils (Kyriakides et al. 1998). The
abnormally organized collagen matrix might be caused by
increased levels of MMP-2 and MMP-9 in wounds of TSP-
2-null mice (Bornstein et al. 2004). The relevance of
modulation of MMP activities by TSP-2 was supported by
the observation that peak levels of MMP-2 and MMP-9 in
the wounds of TSP-2-null mice coincide with the highest
content of TSP-2 in WT wounds. Together these studies
indicate that TSP-2 is a crucial regulator of the integrity of
the cardiac ECM during maturation of the infarct scar,
presumably via regulation of MMP activity, and subsequent
deposition of a cross-linked collagen matrix (Fig. 2).
Thrombospondin polymorphisms and myocardial infarction
The importance of TSPs in infarct healing has been
established in the above-described mouse models of acute
MI. However, it is important to know whether TSPs are
also involved in human cardiac diseases. This paragraph
describes their potential role in the progression of athero-
sclerosis, plaque rupture and platelet biology, thereby
linking TSP gene alterations to the risk of MI.
Topol et al. were the first to describe a link between
single nucleotide polymorphisms (SNPs) in TSP genes and
MI (Topol et al. 2001). The SNPs affected the amino acid
sequences of TSP-1 (Asn700Ser, 2210A/G) and TSP-4
(Ala387Pro, 1186G/C), whereas for TSP-2 a SNP was
found in the 3’ untranslated region (UTR) (3949T/G). The
SNP in TSP-1 lowers its capacity for calcium binding, an
alteration that could influence the structure and function of
this matricellular protein. In platelets, the TSP-1 SNP is
associated with increased cell-surface expression of TSP-1
and enhanced platelet aggregation. These results provide a
mechanism for the increased risk of MI in individuals
bearing the TSP-1 SNP. The TSP-4 387Pro variant is
dominant, and exhibits increased calcium binding, relative
to WT TSP-4, although the expression and processing of
TSP-4 are not affected in cells with this SNP. The TSP-4
SNP alters endothelial cell behavior by its interference with
adhesion and proliferation. Blocking endothelial cell repair,
increasing smooth muscle cell proliferation, and augment-
ing neutrophil activation by the TSP-4 387Pro variant could
result in atherosclerotic lesions and an increased risk of MI.
The SNP found in the 3’ UTR of TSP-2 mRNA results in a
different secondary structure, as predicted by the M-fold
model, which might affect protein expression. Consistent
with this possibility, the expression of a luciferase reporter
with the TSP-2 3949G variant was substantially lower in
human umbilical vein endothelial cells, in comparison to
that of the TSP-2 3949T variant. These data suggest
decreased expression of TSP-2 in the vascular wall of
individuals with the 3949G SNP.
However, the association between TSP SNPs and MI is
not a consistent finding. Koch et al. determined the
genotypes related to the SNPs in the genes for TSP-1,
TSP-2, and TSP-4 in a large, case-control sample of MI and
performed a meta-analysis of data from their own and from
previous studies (Koch et al. 2008). They described mildly,
but significantly, elevated risks of MI in individuals
carrying the TSP-2 3949G SNP, whereas no correlation
was found for the TSP-1 and TSP-4 SNP variant with MI.
Their meta-analysis of available data revealed that none of
the polymorphisms was linked with the risk of MI.
Because studies with TSP-null mice indicate a role for
TSP-1 and TSP-2 in infarct healing, it would be tempting to
investigate the influence of TSP SNPs on infarct healing
and the transition toward heart failure. These studies would
provide evidence confirming the importance of TSPs in
cardiac remodeling after acute MI.
Thrombospondins as key players during cardiac
remodeling
In the complex process of cardiac remodeling, many growth
factors, cytokines, and other proteins have been recognized
as key players. Lately, non-structural proteins residing in the
ECM, such as certain matricellular proteins including
periostin, were highlighted as important factors influencing
cardiac remodeling. In this review, we have discussed the
functions and possible actions of the matricellular TSPs
during cardiac remodeling (Figs. 1 and 2).
First, evidence supporting the notion that TSPs are
involved in cardiac remodeling was provided by different
studies that reported upregulation of different TSPs after
cardiac injury. Several groups reported elevated expression
of TSP-1, TSP-2, TSP-3 and TSP-4 in different models of
pressure overload (Table 1). Schroen et al. identified TSP-2
as an important regulator of the transition from compen-
sated LVH towards heart failure (Schroen et al. 2004).
TSP-2-null mice, after Ang-II infusion, showed advanced
myocardial rupture accompanied by increased levels of
MMP-2. MMPs and TIMPs are actively involved in
hypertrophic cardiac remodeling. TSP-1 and TSP-2 contain
TSR motifs that are able to interact with MMPs to regulate
their activity. Therefore, TSPs are likely to play a role in the
process of LVH by controlling the MMP-TIMP balance and
thereby regulating breakdown of the ECM. A second
mechanism by which TSPs could affect LVH depends on
the regulation of the activity of the pro-fibrotic, anti-
inflammatory factor, TGF-β1, which is synthesized after
induction of the RAS and contributes to myocardial
remodeling. TSP-1 binds TGF-β1 via its GGWSHW motif
and can subsequently activate the protein through its KRFK
motif.
Thrombospondins and cardiac remodeling 209The complex domain structure of TSP-1 and TSP-2
allows them to interact with a large number of cell surface
receptors, including integrins and CD47/IAP, that partici-
pate in signal transduction. TSPs could affect the develop-
ment of LVH as regulators of angiogenesis via interactions
with integrins, CD36 and CD47/IAP or as targets of chronic
Akt activation and inhibitors of NO signaling.
Studies that investigated TSPs after MI suggested that
TSP-1 and TSP-2 have distinct functions depending on
their spatiotemporal expression. Models of wound healing
in mice revealed that TSP-1 is markedly induced during
the acute inflammatory phase and drops during later
phases of healing, whereas TSP-2 expression is limited
to a small number of fibroblasts during inflammation and
peaks in the proliferative phase and during scar matura-
tion. In a setting of MI, TSP-1-null infarcts revealed more
inflammation and expansion of the infarct, whereas no
differences in vascularization were reported. These data
indicate that TSP-1 functions to control the inflammatory
response and prevent infarct expansion, most likely via
regulation of TGF-β1 activity during the first stage of
infarct healing. That TSP-2-null mice display pronounced
cardiac rupture after MI, indicates a crucial role for TSP-2
in regulation of the integrity of the cardiac ECM during
remodeling, presumably through regulation of the activities
of MMP-2 and MMP-9.
We speculate that TSPs are crucial mediators of cardiac
remodeling through their influence on various processes,
due to their spatiotemporal expression pattern and structure.
TSPs might directly influence cardiomyocyte function
through interaction with various surface receptors such as
integrins, CD47/IAP, and CD36, whereas they can regulate
ECM remodeling through their effect on MMP activation.
Also, their effects on inflammation and angiogenesis might
be important during cardiac remodeling. Thus, we postulate
that the TSPs are important in a variety of cardiac diseases,
as TSPs can modulate cell behavior through interactions
with different surface receptors, with their specific effects
depending on the cell type and the nature of the remodeling
process.
Studies addressing the role of TSPs in remodeling after
cardiac injury are limited. However, in this review we
present strong evidence that TSPs are key players during
hypertrophic and ischemic cardiac remodeling. Increasing
our understanding of these proteins affords new opportuni-
ties for intervention to prevent the transition towards heart
failure in patients suffering from cardiac diseases.
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